Patients with low expression of VEGF-D ( 0 , 1 ) benefited from bevacizumab treatment ( PFS hazard ratio ( HR ) ( C vs CBCBM ) , 0.21 ; 95 % CI , 0.080.55 ; overall survival ( OS ) HR , 0.35 ; 95 % CI , 0.130.90 ) .